Clin2
NCT07263919Possibly a fitRecruiting

Chemo plus cadonilimab before surgery for esophageal cancer

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Treatments studied

Part of Cancer clinical trials.

This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
90 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have a type of esophageal cancer called squamous cell carcinoma that doctors believe can be fully removed with surgery.
  • You are in generally good health (able to perform daily activities with little help).
  • You have not had prior treatment for this esophageal cancer (like chemo, radiation, or surgery).
  • You do not have cancer that has spread to other parts of the body.
  • You agree to use effective birth control if you or your partner could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06475196Enrolling by invitation
Immunotherapy plus chemo before surgery for esophageal cancer

This trial tests a combination of immunotherapy (sintilimab) and chemotherapy given before surgery for esophageal cancer that can be surgically removed. The goal is to see if this approach helps shrink tumors and improve outcomes.

Xi'an, Shaanxi
NCT06356688Recruiting· Phase 2
Study of chemo plus immunotherapy before surgery for esophageal cancer

This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.

Nanjing, Jiangsu
NCT06426797Not yet recruiting· Phase 2
Immunotherapy and targeted therapy before esophageal cancer surgery

This study tests a combination of two drugs—cadonilimab (an immunotherapy) and anlotinib (a targeted therapy)—given before surgery for advanced esophageal cancer that can still be removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.

NCT07699185Recruiting· Phase 2
Immunotherapy plus chemoradiation before surgery for esophageal cancer

This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.

Wuhan, Hubei
NCT07016724Recruiting· Phase 2
Study of radiation and chemo with cadonilizumab for esophageal cancer

This trial tests combining radiation, chemotherapy, and the drug cadonilizumab before surgery for locally advanced esophageal squamous cell cancer. It aims to shrink the tumor and improve treatment outcomes.

Zhengzhou, Henan
NCT06715501Enrolling by invitation
Testing cadonilimab with chemo and radiation for advanced esophageal cancer

This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.

Ningbo, Zhejiang

Hear when a new Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.